Rx Switches Where Everybody Wins: Members, Prescribers, and Your Plan

Employer care teams are doing exactly what they should be doing: focusing on the member in front of them, not the formulary tier behind them. Pharmacists and prescribers are optimizing for clinical outcomes at the point of care, not plan spend, member cost share, or your renewal.

Which is exactly why measurable Rx savings keep slipping through the cracks. Nobody's being careless. Cost simply isn't the question being asked in the exam room.

Here’s the thing: A meaningful share of plan spend isn’t tied up in hard clinical tradeoffs. It’s sitting in switches so clinically straightforward that most prescribers would consider them without hesitation if the information showed up at the right moment. Same active ingredient. Different price tag.

Here are six real examples, drawn from actual savings we’ve seen from Scripta’s own clients. No hypotheticals. This is what's happening on real plans, right now.

Quick definition, since it matters here: a "switch" isn't a compromise. It's a lower-cost, clinically appropriate alternative. The same active ingredient (or a medication in the same class with well-established interchangeability) that a physician reviews and approves. Nothing changes at the pharmacy counter without that sign-off.

Easy switches that can save your patients and the plan

Current Medication	Lower-Cost Alternative	Member Savings	Plan Savings	Total Savings
Vyvanse	Lisdexamfetamine	$13,334.32	$36,818.07	$50,152.39
Adderall XR	Amphetamine-Dextroamphetamine ER	$2,964.09	$8,900.37	$11,864.46
Concerta	Methylphenidate ER (OSM)	$884.96	$6,457.54	$7,342.50
Synthroid	Levothyroxine Sodium	$6,610.38	$845.64	$7,456.02
Olmesartan	Losartan	$4,073.00	$7,031.00	$11,104.00
Escitalopram	Citalopram	$8,285.00	$11,966.00	$20,251.00

Not all switches are created equal — and that's fine

It’s worth being straight about this: four of these (Vyvanse, Adderall XR, Concerta, Synthroid) are brand-to-generic swaps of the same medication. About as close to zero clinical debate as it gets.

The other two — Olmesartan to Losartan, and Escitalopram to Citalopram — are same-class alternatives with well-established clinical interchangeability, but they involve different medications. These remain candidates for physician consideration, not switches to make unilaterally. That's not a caveat that undercuts the case — it's the whole point. Every switch on this list is a physician-approved decision. Scripta surfaces the option; the prescriber always makes the call.

Why this doesn't happen on its own

Clinic-based prescribers and in-house pharmacists aren't seeing plan-level cost data when they're writing a script. They may not have the context, or the moment, to raise a lower-cost, clinically appropriate alternative. And members rarely know to ask. Everyone in the chain is doing their job; the system just isn't set up to surface cost information at the one moment it would matter most.

That's the gap that Scripta’s Provider Navigator is built to close: surfacing lower-cost, clinically appropriate alternatives right at the point of prescribing, so the option is visible before the script is written, not after the claim is paid.

Scripta’s Provider Navigator was created by our clinicians who understand how prescribing really happens. Our P&T Committee of nearly 30 practicing physicians and licensed pharmacists ensures that:

• Every recommendation is clinically sound

• Every workflow mirrors real clinical practice

• Every savings opportunity supports better outcomes

When prescribers use Provider Navigator, members leave the visit knowing exactly what their medication will cost, and with an option that fits both their treatment plan and their budget. No pharmacy counter surprises. No callbacks. Just a smoother, more supportive experience.

Get this in front of the people who can act on it

If you work with an in-house pharmacy or care team, consider sharing this content with them. Prescribers and pharmacists are the ones positioned to act on it, and most will, once cost-effective options are on their radar. Consider this your starting point for that conversation.